From Casetext: Smarter Legal Research

Bayer v. Sterling Drug

U.S.
Feb 25, 1963
372 U.S. 929 (1963)

Summary

holding antitrust cause of action for exclusion of plaintiff from United States drug market, relying on unlawful contract of sale of trademarks and patents executed in pre-limitations period by plaintiff's predecessor and defendant's predecessor, barred by statute of limitations because plaintiff alleged no overt acts of exclusion by defendants within limitations period

Summary of this case from Imperial Point Colonnades v. Mangurian

Opinion

Nos. 652, 653.

February 25, 1963.

Thurman Arnold, Milton V. Freeman and Edgar H. Brenner for petitioner.

John T. Cahill, George S. Hills and Robert G. Zeller for respondent.


C.A. 3d Cir. Certiorari denied.

Reported below: 307 F. 2d 207, 210.


Summaries of

Bayer v. Sterling Drug

U.S.
Feb 25, 1963
372 U.S. 929 (1963)

holding antitrust cause of action for exclusion of plaintiff from United States drug market, relying on unlawful contract of sale of trademarks and patents executed in pre-limitations period by plaintiff's predecessor and defendant's predecessor, barred by statute of limitations because plaintiff alleged no overt acts of exclusion by defendants within limitations period

Summary of this case from Imperial Point Colonnades v. Mangurian
Case details for

Bayer v. Sterling Drug

Case Details

Full title:FARBENFABRIKEN BAYER A. G. v. STERLING DRUG, INC

Court:U.S.

Date published: Feb 25, 1963

Citations

372 U.S. 929 (1963)

Citing Cases

Woods Exploration Producing Co. v. Aluminum Co. of America

Nevertheless, prior cases have amply demonstrated that conduct designed to barricade access to markets or…

United States v. Beigel

Compare United States v. Bentvena, 319 F.2d 916, 927, 929 (2d Cir.), cert. denied sub nom. Ormento v. United…